|
Delayed
Nasdaq
16:22:13 19/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.3550 USD | -1.39% |
|
-4.05% | -44.46% |
| 08-06 | Cytosorbents Corporation, Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Cytosorbents Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Cytosorbents Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 22.62 | - | - |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -43.65% | - | - |
| Enterprise Value (EV) | 182.2 | 67.64 | 57.95 | 49.76 | 40.14 | 22.62 | 22.62 | 22.62 |
| Change | - | -62.87% | -14.31% | -14.14% | -19.32% | -43.65% | 0% | 0% |
| P/E | -7.35x | -2.07x | -1.73x | -2.39x | -4.92x | -1.64x | - | 12x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.1x | 0.1x | 0.1x | -0x | - | - |
| Capitalization / Revenue | 4.22x | 1.95x | 1.59x | 1.27x | 1.08x | 0.58x | 0.51x | 0.44x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.58x | 0.51x | 0.44x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -2.95x | -28.9x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.35x | -174x | 9.91x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.57 | -0.75 | -0.64 | -0.38 | -0.13 | -0.22 | - | 0.03 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 43.17 | 34.69 | 36.35 | 39.2 | 37.06 | 38.88 | 44.16 | 51.6 |
| EBITDA 1 | -15.81 | -26.84 | -26.05 | -11.46 | -13.3 | -7.667 | -0.7823 | - |
| EBIT 1 | -22.74 | -31.52 | -31.21 | -16.79 | -14.24 | -9.639 | -0.13 | 2.284 |
| Net income 1 | -24.56 | -32.81 | -28.51 | -20.72 | -8.198 | -13.91 | -0.13 | 2.284 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 4.1900 | 1.5500 | 1.1100 | 0.9100 | 0.6392 | 0.3600 | 0.3600 | 0.3600 |
| Nbr of stocks (in thousands) | 43,476 | 43,636 | 52,212 | 54,680 | 62,804 | 62,843 | - | - |
| Announcement Date | 08/03/22 | 09/03/23 | 14/03/24 | 31/03/25 | 25/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.64x | - | - | - | 22.62M | |
| 29.33x | 5.21x | 19.98x | 0.31% | 218B | |
| 33.45x | 6.1x | 19.33x | 0.71% | 140B | |
| 42.92x | 11.18x | 24.72x | -.--% | 138B | |
| 18.87x | 3.83x | 12.45x | -.--% | 73.14B | |
| 35.95x | 7.22x | 22.84x | -.--% | 52.44B | |
| 19.55x | 2.35x | 11.73x | 2.6% | 50.85B | |
| 28.87x | 5.76x | 19.69x | 0.69% | 41.92B | |
| 85.71x | 6.72x | 20.37x | -.--% | 39.42B | |
| 15.55x | 1.79x | 9.99x | 0.22% | 32.81B | |
| Average | 30.86x | 5.57x | 17.90x | 0.5% | 78.69B | |
| Weighted average by Cap. | 33.51x | 6.20x | 19.24x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTSO Stock
- Valuation Cytosorbents Corporation
Select your edition
All financial news and data tailored to specific country editions
